

Haematologica
HAEMATOL/2018/203430
Version 3

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in
TP53-mutated chronic lymphocytic leukemia cells

Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky,
Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz,
Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova,
Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil
Paruch, and Martin Trbusek

Disclosures: All authors declare no conflict of interest.

Contributions: KP and PK developed inhibitor MU380; MBou, JZ, MBor, AO, VS, MM, MH, KS, SD, and MK performed laboratory experiments; JV performed xenograft experiments; MBou, JC, and JJ analyzed samples from in vivo tumors; MBou performed statistical analyses; YB, JM, and ZJ contributed clinical samples; MT, KP, and MBou designed experiments and performed data analyses; MT, KP, and MBou wrote the manuscript; MT and KP supervised the study.